"Express Mail" mailing label number EL424749236US

Date of Deposit November 7, 2000.





FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE CASE NO. 10727/3 (REV. 5-93) PATENT AND TRADEMARK OFFICE U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) 674969 CONCERNING A FILING UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. DATE CLAIMED INTERNATIONAL FILING DATE PCT/NO00/00098 21 March 2000 22 March 1999 TITLE OF INVENTION METHODS IN TRANSMISSION OF FILES IN A DATA COMMUNICATION NETWORK APPLICANT(S) FOR DO/EO/US Arild Fuldseth et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: ∑ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371 This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather 3. than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. A copy of the International Application as filed (35 U.S.C. 371(c)(2)). is transmitted herewith (required only if not transmitted by the International Bureau). b. has been transmitted by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). П C. M A translation of the International Application into English (35 U.S.C. 371(c)(2)). 6. 7. L Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). are transmitted herewith (required only if not transmitted by the International Bureau). عندأ have been transmitted by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 8. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)) and/or amendments under Article 34. Items 11. to 16. Below concern other document(s) or information included: 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. 🔯 An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 14. A substitute specification. Headings in compliance with standard U.S. practice have been added. 15. A Power of Attorney and/or address letter. Other items or information: Request, copy of first page of Priority Document, Notice Informing Applicant of 16.🔯 Communication of the International Application to Designated Offices, Notification of Receipt of Record copy, Notification

Concerning Submission or Transmittal of Priority Document, Notification of Transmittal of Search Report, Cited References

528 Rec'd PCT/PTO 0 7 NOV 2000

U.S. APPLICATION NO TIME COMP. See & C.FR. 150.9 6 9 INTERNATIONAL APPLICATION NO. PCT/NO00/00098		CASE NO. 10727/3			
17. The following fees are submitted:				CALCULATIONS	PTO USE ONLY
Basic National Fee (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO\$860.00					
International preliminary examination fee paid to USPTO (37 CFR 1.492(a)(1))\$690.00					
No international preliminary examination fee paid to USPTO					
(37 CFR 1.482) but international search fee paid to USPTO					
(37 CFR 1.492(a)(2)) \$710.00					
Neither international preliminary examination fee (37					•
CFR 1.482) por international search fee (37 CFR					
1.492(a)(3)) paid to USPTO\$1,000.00					
International preliminary examination fee paid to					
USPTO (37 CFR 1.482) and all claims satisfied					
provisions of PCT Article 33(1)-(4)\$100.00					
ENTED ADDRODDIATE DAGIO FEE AMOUNT				\$1000	-
ENTER APPROPRIATE BASIC FEE AMOUNT				\$1000	
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 30 months from the earliest claimed approximately periority date (37 CFR 1.492(e)).					
Claims	Number Filed	Number Extra	Rate		
≇otal Claims	16- 20 =	0	x \$ 18.00	\$0.00	
##idependent Claims 2- 3 = 0 x \$ 80.00				\$0.00	
**Afultiple dependent claim(s) if Applicable) 0 + \$270.00				\$0.00	
TOTAL OF ABOVE CALCUATIONS =				\$1000	
Reduction by ½ for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37				\$500.00	
(基下 1.9, 1.27, 1.28) SUBTOTAL =				\$500	
Surcharge of \$130.00 for furnishing the English translation later than the 20 30 months from the earliest				4000	
₌claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE=				\$500	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an				40.00	
appropriate cover sheet (37 CFR 3.28, 3.31), \$40.00 per property + TOTAL FEES ENCLOSED=				\$540	
				Amount to be	\$
A check in the amount of \$540 to cover the above fees is enclosed.				refunded	
				charged	\$
A check in the amount of \$540 to cover the above fees is enclosed.					
b. Please charge my Deposit Account No. 23-1925 in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. Main the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
Send All Correspondence to:					
Brinks Hofer Gilson & Lione				12 5 das	,
P.O. Box 10395 Chicago, II, 60610					
Chicago, IL 60610 Signature					
F. David AuBuchon					
Name					
20,493 Registration Number					
		ll vedisii	adort (valide)		

Rev. Oct.-00 C:\ALL\FDA\10727\3\Transmittal.doc